Study to Compare Bioavailability of GLPG1972 Given as 2 Different Tablet Formulations Versus an Oral Solution

Inclusion criteria

• Male between 18 and 50 years of age, inclusive,
• A body mass index (BMI) between 18-30 kg/m², inclusive, weight of at least 50 kg.
• Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and laboratory findings.
• Discontinuation of all medications except occasional paracetamol at least 2 weeks or 5 half-lives prior to the first study drug administration.
• Non-smokers and not using any nicotine-containing products.
• Negative urine drug screen and alcohol breath test.
• Current sexually active male agrees to use adequate contraception
• Willing to consume a non-vegetarian high-fat and high-calorie breakfast
• Able and willing to sign the ICF

Exclusion criteria

• Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug
• Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) or any history of hepatitis from any cause with the exception of hepatitis A.
• History of or a current immunosuppressive condition
• Symptoms of clinically significant illness in the 3 months before the initial study drug administration.
• History of malignancy within the past 5 years
• Clinically relevant abnormalities detected on ECG regarding either rhythm or conduction (e.g. QTcF >450 msec, or a known long QT syndrome).
• Presence of abnormal liver function
• Renal function with an estimated creatinine clearance <80 ml/min based on the Cockcroft-Gault formula.
• Presence of any condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
• Clinically relevant abnormalities detected on "vital signs"
• Dietary requirements precluding participation.
• Significant blood loss including blood donation or had a transfusion of any blood product within 12 weeks
• Hemoglobin level <7.5 mmol/L (12 g/dL).
• Active drug or alcohol abuse within 2 years prior to the initial study drug administration.
• Current (2 weeks before screening) and planned uninterrupted consumption of large quantities (> 6 cups) of coffee
• Administration of an injectable drug within 30 days prior to the initial study drug administration.
• Concurrent participation, or participation in a drug/device study within 8 weeks or 5 half-lives of the drug or within 6 months for biologicals
• Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff